An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:<\/p>
http://www.legislation.gov.uk/uksi/2018/1055/impacts<\/a><\/p> This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.<\/p> In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:<\/p> https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-10", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-10T13:23:02.387Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the accuracy of evidence base on the cost-effectiveness of medical cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"}
}
, "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"}
, "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"}
], "uin" : "257705"}
, {"_about" : "http://data.parliament.uk/resources/1128442", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1128442/answer", "answerText" : {"_value" : " The Department for International Trade and the Department of Health and Social Care are not specifically collecting data on the growth of the market for cannabis based products for medicinal use in the United Kingdom.<\/ins><\/p> However, data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications for medicinal cannabis and the Home Office has received increased numbers of licence applications.<\/ins><\/p> In addition, UK companies exporting these products and foreign companies looking to invest in the UK have full access to government support, where they have the necessary authorisations from the MHRA and Home Office and a relevant Export Licence.<\/ins><\/p><\/ins><\/p> The Care Quality Commission (CQC) is the independent regulator of health and adult social care providers in England and has a key responsibility in the overall assurance of safety and quality of health and adult social care services. The CQC monitors its own effectiveness of inspection methods in care home and other health settings in a number of ways to ensure that everyone is safe from harm, abuse and neglect. In addition, the CQC is currently collaborating with the University of Manchester\u2019s Alliance Manchester Business School on research exploring the impact of the CQC on the quality of care.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-06-10", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-10T15:18:33.243Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Care Homes: Inspections"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made on the effectiveness of inspection methods in care homes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4464", "label" : {"_value" : "Biography information for Melanie Onn"}
}
, "tablingMemberConstituency" : {"_value" : "Great Grimsby"}
, "tablingMemberPrinted" : [{"_value" : "Melanie Onn"}
], "uin" : "257773"}
, {"_about" : "http://data.parliament.uk/resources/1128462", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1128462/answer", "answerText" : {"_value" : " The Government has given councils access to up to £3.9 billion for 2019-20. This includes a £240 million adult social care winter fund to help local authorities alleviate winter pressures on the National Health Service, getting patients home quicker and freeing up hospital beds across England. As a result of these measures, funding available for adult social care is increasing by 9% in real terms from 2015-16 to 2019-20, allowing councils to support more people including the elderly and to sustain a diverse care market.<\/p> The Disabled Facilities Grant supports older and disabled people, on low incomes, to adapt their homes to make them suitable for their needs. The amount of funding available has more than doubled from £220 million in 2015-16 to £505 million in 2019-20.<\/p> <\/p> Furthermore, the most recent data shows public spending figures on adult social care amounted to £17.1 billion in 2017-18 with £5.3 billion spent on older adults.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-06-10", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-10T15:39:43.303Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Social Services: Older People"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what (a) funding and (b) grants her Department makes available to elderly people in relation to the provision of social care.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4496", "label" : {"_value" : "Biography information for Scott Mann"}
}
, "tablingMemberConstituency" : {"_value" : "North Cornwall"}
, "tablingMemberPrinted" : [{"_value" : "Scott Mann"}
], "uin" : "257783"}
, {"_about" : "http://data.parliament.uk/resources/1128505", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1128505/answer", "answerText" : {"_value" : " The new Primary Care Network arrangements will not prevent patients seeing their preferred professional at their practice. The core general practice contract will still include a requirement for each contractor to ensure that for each of its registered patients, there is assigned an accountable general medical practitioner (an \u2018accountable GP\u2019).<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-10", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-06-10T15:24:15.39Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Primary Care Networks: General Practitioners"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether safeguards are in place to ensure that patients' rights to continuity of care with their named GP will be protected in the new Primary Care Network contract, published in March 2019.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4649", "label" : {"_value" : "Biography information for Thelma Walker"}
}
, "tablingMemberConstituency" : {"_value" : "Colne Valley"}
, "tablingMemberPrinted" : [{"_value" : "Thelma Walker"}
], "uin" : "257814"}
, {"_about" : "http://data.parliament.uk/resources/1128560", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1128560/answer", "answerText" : {"_value" : " Estimates of the potential reduction in daily calories consumed by children as a result of the measures set out in the consultations on restricting promotions of products high in fat, sugar and salt, and introducing further advertising restrictions on such products are provided in the impact assessments published alongside each consultation. These are available at the following links:<\/p> <\/p> \u2018Restricting volume promotions for high fat, sugar and salt (HFSS) products\u2019 impact assessment:<\/p> https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/770705/impact-assessment-for-restricting-volume-promotions-for-HFSS-products.pdf<\/a><\/p> \u2018Restricting checkout, end-of-aisle, and store entrance sales of food and drinks high in fat, salt and sugar (HFSS) impact assessment:<\/p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:<\/del><\/p>http://www.legislation.gov.uk/uksi/2018/1055/impacts<\/a><\/del><\/p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.<\/del><\/p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:<\/del><\/p>https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf<\/a><\/del><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-06-10", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1128442/answer/previousversion/121340", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
}
, "questionFirstAnswered" : [{"_value" : "2019-06-10T13:18:03.37Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2019-06-11T11:31:21.83Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will publish the evidence (a) his Department and (b) the Department for International Trade holds on growing a market for prescribed medicinal cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"}
}
, "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"}
, "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"}
], "uin" : "257706"}
, {"_about" : "http://data.parliament.uk/resources/1128455", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1128455/answer", "answerText" : {"_value" : "